The Zhitong Finance App learned that Jitai Technology-P (07666) rose by more than 9%. As of press release, it had risen 4.02% to HK$11.64, with a turnover of HK$71.518,900.

According to news, on October 19, Jietai Technology-P and the world-renowned multinational pharmaceutical company Lilai reached a partnership with the largest AI-driven extra-hepatic LNP delivery platform in the world. It is also the first generative AI-LNP platform strategic cooperation in China. In this major strategic cooperation with a total cost of up to 1.1 billion US dollars, the two sides will focus on research and discovery of novel LNP (lipid nanoparticle) delivery solutions to explore tissue-specific delivery solutions that support various treatment models.

As an AI nano-delivery platform independently developed by Jietai Technology, nanoForge uses a self-developed “dry test+wet test+smart body” integrated innovation framework, and has achieved a complete chain covering AI protein generation, in vivo delivery technology, and next-generation immunotherapy development. In recent years, the biological AI critical infrastructure nanoForge platform developed by Jietai Technology Innovation has been widely recognized by international professional investment institutions and leading multinational pharmaceutical companies. The major strategic partnership between the company and Eli Lilly clearly once again validates NanoForge's strong ability to continuously produce global value innovation assets.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.